ALQGC — Quantum Genomics SA Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Quantum Genomics FY Net Loss Narrows To 9.1 Million Euros
Brief: Quantum Genomics Appoints Benoit Gueugnon As Vice President Of Finance
Brief: Quantum Genomics Begins Phase III FRESH Trial In Difficult-To-Treat And Resistant Hypertension
Brief: Quantum Genomics Enters Agreement On Firibastat
Brief: Quantum Genomics In Talks To Sign Partnership Covering Latin America
Brief: Quantum Genomics H1 Operating Loss Narrows To 5.3 Million Euros
Brief: Quantum Genomics Announces Positive FDA Feedback
Brief: Quantum Genomics Reaches Firibastat Development Milestone
Brief: Quantum Genomics Enrolls First Patient In Quorum Phase IIb Study
Brief: Quantum Genomics: Data Demonstrate Efficacy Of QGC006 As An Antihypertensive Agent
Brief: Quantum Genomics Receives First Regulatory And Ethics Approvals To Initiate Phase IIb Quorum Study Of Firibastat In Heart Failure
Brief: Quantum Genomics FY Net Loss Widens To 12 Million Euros
Brief: Quantum Genomics Announces Positive Results From New Preclinical Studies On Firibastat
Brief: Quantum Genomics Completes Enrollment In Its Pharmacokinetic Clinical Study Of Firibastat
Brief: Quantum Genomics Announces Positive Study Results For Firibastat
Brief: Quantum Genomics Presents Results On NEW-HOPE And QUORUM
Brief: Quantum Genomics Prepares Launch Of Phase III Study In Treatment Of Resistant Hypertension
Brief: Quantum Genomics Announces Top-Line Results From Its Phase 2b NEW-HOPE Trial Of Firibastat
Brief: Quantum Genomics Gets Approval For Firibastat Clinical Evaluation